GlassScriptPhysician profile
Briles Christenson
NPI 1881320554
$963.88
in general payments reported to CMS, 2019-2025
17 companies · $247 in 2025
The $247 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $717 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $963.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $192.85 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $169.59 | 2024-2025 | Fanapt |
| Corium, LLC | $94.07 | 2024-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $93.60 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Lundbeck LLC | $81.69 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.29 | 2024 | Caplyta |
| Noven Therapeutics, LLC | $46.97 | 2024-2025 | Xelstrym, Secuado |
| Takeda Pharmaceuticals U.S.A., INC. | $46.27 | 2024-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $32.51 | 2024 | |
| Neurocrine Biosciences, INC. | $29.35 | 2024-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $19.31 | 2024 | Cobenfy |
| Janssen Pharmaceuticals, INC | $18.53 | 2024 | Spravato |
| Alkermes, INC. | $17.70 | 2024 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $17.44 | 2025 | Austedo Xr |
| Neos Therapeutics, LP | $14.82 | 2025 | Adzenys Xr-Odt |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $14.37 | 2025 | Qelbree |
| Tris Pharma INC | $13.52 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Briles Christenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.